Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC) (TASC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00524771|
Recruitment Status : Completed
First Posted : September 5, 2007
Results First Posted : April 9, 2014
Last Update Posted : April 9, 2014
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||34100 participants|
|Official Title:||Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC)|
|Study Start Date :||September 2007|
|Actual Primary Completion Date :||March 2012|
|Actual Study Completion Date :||June 2012|
Users of NuvaRing
Users of combined oral contraceptives
- Number of Participants With Venous Thromboembolism (VTE) [ Time Frame: Time to event analysis within 48 months ]Venous thromboembolism (VTE) associated with the use of hormonal contraceptives that contain both an estrogen and progestin.
- Number of Participants With Arterial Thromboembolism (ATE) [ Time Frame: Time to event analysis within 48 months ]Arterial Thromboembolism (ATE) associated with the use of hormonal contraceptives that contain both an estrogen and progestin.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00524771
|Berlin Center for Epidemiology and Health Research|
|Berlin, Germany, 10115|
|Principal Investigator:||Juergen C Dinger, MD, PhD||Center for Epidemiology and Health Research Berlin, Germany|